Trump’s drug-pricing plan and a potential Theranos 2.0

How likely is it for President Trump’s new drug-pricing plan to be implemented? Why have investors seemed unbothered by the proposal? And will we see a return of Elizabeth Holmes’ blood-testing ambitions?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about the mixed sentiment in biotech markets these days and a new blood-testing company formed by Holmes’ husband.